XNCR
Xencor Inc
NASDAQ · Biotechnology
$11.61
+0.79 (+7.30%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 133.35M | 180.73M | 231.54M | 205.11M | 207.84M |
| Net Income | -280,733,131 | -342,450,281 | -11,326,541 | -12,900,416 | -11,029,247 |
| EPS | — | — | — | — | — |
| Profit Margin | -210.5% | -200.0% | -4.9% | -6.3% | -5.3% |
| Rev Growth | -26.2% | -26.2% | -3.4% | +24.6% | -9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 88.61M | 88.61M | 69.55M | 77.39M | 67.20M |
| Total Equity | 367.05M | 367.05M | 526.59M | 595.63M | 536.70M |
| D/E Ratio | 0.24 | 0.24 | 0.13 | 0.13 | 0.13 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -225,292,949 | -290,089,863 | -15,943,249 | -15,864,221 | -15,646,651 |
| Free Cash Flow | — | — | -7,053,340 | -6,278,593 | -9,889,518 |